MA35724B1 - Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production. - Google Patents

Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production.

Info

Publication number
MA35724B1
MA35724B1 MA37104A MA37104A MA35724B1 MA 35724 B1 MA35724 B1 MA 35724B1 MA 37104 A MA37104 A MA 37104A MA 37104 A MA37104 A MA 37104A MA 35724 B1 MA35724 B1 MA 35724B1
Authority
MA
Morocco
Prior art keywords
antibody molecules
specificity
human
methods
therapeutic uses
Prior art date
Application number
MA37104A
Other languages
English (en)
Inventor
Ralph Adams
Pallavi Bhatta
Sam Phillip Heywood
David Paul Humphreys
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47388492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35724(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of MA35724B1 publication Critical patent/MA35724B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production.
MA37104A 2011-11-11 2014-06-05 Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production. MA35724B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558545P 2011-11-11 2011-11-11
PCT/EP2012/072325 WO2013068563A2 (fr) 2011-11-11 2012-11-09 Molécules d'anticorps ayant une spécificité pour ox40 humain

Publications (1)

Publication Number Publication Date
MA35724B1 true MA35724B1 (fr) 2014-12-01

Family

ID=47388492

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37104A MA35724B1 (fr) 2011-11-11 2014-06-05 Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production.

Country Status (35)

Country Link
US (2) US9040048B2 (fr)
EP (1) EP2776469B1 (fr)
JP (1) JP6367714B2 (fr)
KR (1) KR102071054B1 (fr)
CN (1) CN103946240B (fr)
AP (1) AP2014007668A0 (fr)
AR (1) AR088820A1 (fr)
AU (1) AU2012333997B2 (fr)
BR (1) BR112014011404A2 (fr)
CA (1) CA2855174C (fr)
CL (1) CL2014001193A1 (fr)
CO (1) CO7010784A2 (fr)
CY (1) CY1122073T1 (fr)
DK (1) DK2776469T3 (fr)
EA (1) EA035112B1 (fr)
EC (1) ECSP14000329A (fr)
ES (1) ES2737998T3 (fr)
HR (1) HRP20191219T1 (fr)
HU (1) HUE044333T2 (fr)
IL (1) IL232420B (fr)
LT (1) LT2776469T (fr)
MA (1) MA35724B1 (fr)
MX (1) MX358391B (fr)
MY (1) MY183795A (fr)
PE (1) PE20141995A1 (fr)
PH (1) PH12014500946A1 (fr)
PL (1) PL2776469T3 (fr)
PT (1) PT2776469T (fr)
SG (1) SG11201402093RA (fr)
SI (1) SI2776469T1 (fr)
TN (1) TN2014000206A1 (fr)
TR (1) TR201910721T4 (fr)
TW (1) TWI588155B (fr)
UA (1) UA112203C2 (fr)
WO (1) WO2013068563A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398498B1 (fr) * 2009-02-17 2018-09-05 UCB Biopharma SPRL Molécules d'anticorps ayant une spécificité pour ox40 humain
ES2667258T3 (es) * 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
PL2609118T3 (pl) 2010-08-23 2017-07-31 Board Of Regents, The University Of Texas System Przeciwciała anty-OX40 i sposoby ich stosowania
US10752676B2 (en) * 2011-09-16 2020-08-25 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
NZ712903A (en) 2013-03-18 2018-07-27 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
WO2015041515A1 (fr) 2013-09-19 2015-03-26 N.V. Nutricia Procédé amélioré d'humanisation de lait animal écrémé
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
HRP20230046T1 (hr) 2015-03-03 2023-03-03 Kymab Limited Protutijela, upotreba i postupci
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
PH12017502013B1 (en) * 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
MA43017A (fr) * 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
CN108137684B (zh) * 2015-10-15 2022-03-08 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
CA3006963A1 (fr) * 2015-12-03 2017-06-08 Ludwig Institute For Cancer Research Ltd. Anticorps anti-ox40 et leurs procedes d'utilisation
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP3538152A4 (fr) 2016-11-09 2020-09-30 Agenus Inc. Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
US12296285B2 (en) 2019-08-02 2025-05-13 UCB Biopharma SRL Methods for purifying antibodies
EP4076434A1 (fr) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CA3214085A1 (fr) 2021-03-31 2022-10-06 Darby Rye Schmidt Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
EP4363059A1 (fr) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Cellules immunitaires modifiées pour favoriser la thanotransmission de phényléthanolamines et leurs utilisations
EP4598946A1 (fr) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer
WO2024151687A1 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Commutateurs génétiques et leur utilisation dans le traitement du cancer
WO2025248017A1 (fr) 2024-05-31 2025-12-04 UCB Biopharma SRL Procédé de purification de protéines de recombinaison

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US7850965B2 (en) 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
WO2007112054A2 (fr) 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation de la translocation de molecules a travers le tractus gastro-intestinal
CA2679399A1 (fr) 2007-02-27 2008-09-04 Genetech, Inc. Anticorps antagoniste d'ox40, et leur utilisation dans le traitement de maladies inflammatoires et auto-immunes
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
LT2334705T (lt) * 2008-09-26 2017-03-27 Ucb Biopharma Sprl Biologiniai produktai
EP2398498B1 (fr) 2009-02-17 2018-09-05 UCB Biopharma SPRL Molécules d'anticorps ayant une spécificité pour ox40 humain
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
JP5522668B2 (ja) 2010-02-03 2014-06-18 株式会社ブリヂストン タイヤ構成部材の切断装置及び製造方法
SI2776466T1 (sl) * 2011-11-11 2017-12-29 Ucb Biopharma Sprl Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti

Also Published As

Publication number Publication date
EA201400565A1 (ru) 2014-12-30
EA035112B1 (ru) 2020-04-28
PL2776469T3 (pl) 2019-10-31
LT2776469T (lt) 2019-08-12
KR20140097329A (ko) 2014-08-06
CA2855174C (fr) 2021-11-02
CL2014001193A1 (es) 2014-12-26
WO2013068563A3 (fr) 2013-06-27
ECSP14000329A (es) 2016-01-29
HRP20191219T1 (hr) 2019-10-04
KR102071054B1 (ko) 2020-01-29
PE20141995A1 (es) 2014-12-06
HUE044333T2 (hu) 2019-10-28
SG11201402093RA (en) 2014-06-27
WO2013068563A9 (fr) 2014-06-19
US20130243772A1 (en) 2013-09-19
EP2776469A2 (fr) 2014-09-17
AU2012333997A1 (en) 2014-05-29
CN103946240A (zh) 2014-07-23
CN103946240B (zh) 2018-02-23
BR112014011404A2 (pt) 2017-05-30
IL232420B (en) 2019-02-28
DK2776469T3 (da) 2019-07-29
NZ624583A (en) 2015-05-29
US9040048B2 (en) 2015-05-26
SI2776469T1 (sl) 2019-09-30
TWI588155B (zh) 2017-06-21
AU2012333997B2 (en) 2017-08-31
MX2014005564A (es) 2014-11-10
MX358391B (es) 2018-08-17
ES2737998T3 (es) 2020-01-17
TN2014000206A1 (en) 2015-09-30
AP2014007668A0 (en) 2014-05-31
TR201910721T4 (tr) 2019-08-21
AR088820A1 (es) 2014-07-10
UA112203C2 (uk) 2016-08-10
CA2855174A1 (fr) 2013-05-16
IL232420A0 (en) 2014-06-30
WO2013068563A2 (fr) 2013-05-16
PH12014500946A1 (en) 2014-06-09
PT2776469T (pt) 2019-07-25
EP2776469B1 (fr) 2019-04-24
MY183795A (en) 2021-03-16
JP6367714B2 (ja) 2018-08-01
JP2015506910A (ja) 2015-03-05
TW201326205A (zh) 2013-07-01
CO7010784A2 (es) 2014-07-31
CY1122073T1 (el) 2020-11-25
US9873735B2 (en) 2018-01-23
US20160031974A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
MA35724B1 (fr) Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production.
EP2398498A4 (fr) Molécules d'anticorps ayant une spécificité pour ox40 humain
MA34907B1 (fr) Molécules d'anticorps se liant à il-17a et il-17f
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
EA201290988A1 (ru) Стереоселективный синтез фосфорсодержащих активных соединений
UA107827C2 (xx) Антитіло до cd40
PH12017500864A1 (en) Anti-notch1 antibodies
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
EA201101303A1 (ru) Молекулы антител, обладающие связывающей специфичностью в отношении il-13 человека
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
MY147217A (en) Antibody molecules having specificity for human il-06
CR20150153A (es) Tratamiento para artitris reumatoide
PH12013500143A1 (en) A method of treating alzheimer`s disease
EP2576575A4 (fr) Composés conjugués prostaglandine-bisphosphonate, leurs méthodes de fabrication et leurs utilisations
EA201190313A1 (ru) Замещенные пиперидины
EP2892555A4 (fr) Immunogènes d'anticorps de vih-1 largement neutralisants, procédés de génération et utilisations associés
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.